Chemotherapy

The addition of tumor-treating fields to chemotherapy did not prolong survival for women with platinum-resistant ovarian cancer, according to the device’s manufacturer.

Tisotumab vedotin-tftv prolonged OS compared with chemotherapy alone among women with recurrent or metastatic cervical cancer, according to the agent’s manufacturers.

Patients with muscle-invasive bladder cancer receiving dose-dense methotrexate, vinblastine, doxorubicin and cisplatinhad improved OS at 5 years compared with gemcitabine and cisplatin, according to a presentation at ASCO Annual Meeting.

Listening to music during chemotherapy infusion appeared to improve mood and reduce distress among a cohort of patients with cancer, according to study results published in JCO Oncology Practice.

An experimental gene editing cell therapy for sickle cell disease has shown encouraging early results in a phase 1/phase 2 multicenter clinical trial, according to researchers at Cleveland Clinic Children’s.

Healio spoke with Charu Aggarwal, MD, MPH, about results from the Keynote-671 trial presented at this year’s ASCO Annual Meeting.

Women receiving cancer treatment in clinical trials exhibited higher risk for severe symptomatic and hematologic adverse events than their male counterparts, according to a study.

Editor’s note: This is the fourth in a series of five stories from ASCO Voices, a session during ASCO Annual Meeting focused on the human side of oncology.

Intra-arterial administration of gemcitabine conferred a median PFS benefit of 8 months when compared with standard of care for patients with locally advanced pancreatic cancer, according to results of the phase 3 TiGeR-PaC study.

More than one-third of adults with previously untreated stage III non-small cell lung cancer exhibited a pathologic complete response after receiving perioperative nivolumab plus chemotherapy, results of a randomized phase 2 trial showed.